» Articles » PMID: 26277206

[In Vitro Activity of Fosfomycin, Alone or in Combination, Against Clinical Isolates of Carbapenem Resistant Pseudomonas Aeruginosa]

Overview
Date 2015 Aug 17
PMID 26277206
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The increase in microorganisms showing patterns of multi-drug resistance or even pan-drug resistance is of growing concern. Fosfomycin (FO) is well known to be active against a wide variety of microorganisms, including highly resistant strains of Pseudomonas aeruginosa (P. aeruginosa), and can also synergistically act with other molecules.

Methods: This study examines the in vitro activity shown by FO against 120 strains of carbapenem-resistant P. aeruginosa using an agar dilution and a gradient diffusion test. Possible synergistic effects of the combinations of FO/amikacin and FO/ciprofloxacin were also examined using E-test and time-kill techniques.

Results: According to the epidemiological cut-off value (ECOFF) issued by the European Committee on Antimicrobial Susceptibility Testing (EUCAST), our results indicate that over three-quarters of the strains tested would be susceptible to FO treatment, especially if combined with another antimicrobial. The FO/ciprofloxacin combination had a synergistic effect on 40% of the clinical isolates, while for FO/amikacin this effect was only observed in 12% of the isolates.

Conclusion: The appearance of carbapenem-resistant P. aeruginosa strains requires the evaluation by combination therapy. This report suggests that the FO/ciprofloxacin combination can be useful, showing a synergistic effect in 40% of the isolates.

Citing Articles

Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy.

Mensa J, Barberan J, Soriano A, Llinares P, Marco F, Canton R Rev Esp Quimioter. 2018; 31(1):78-100.

PMID: 29480677 PMC: 6159363.


Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study.

Pan A, Mei Q, Ye Y, Li H, Liu B, Li J J Antibiot (Tokyo). 2016; 70(2):166-173.

PMID: 27756910 DOI: 10.1038/ja.2016.124.


Baicalein attenuates the quorum sensing-controlled virulence factors of Pseudomonas aeruginosa and relieves the inflammatory response in P. aeruginosa-infected macrophages by downregulating the MAPK and NFκB signal-transduction pathways.

Luo J, Kong J, Dong B, Huang H, Wang K, Wu L Drug Des Devel Ther. 2016; 10:183-203.

PMID: 26792984 PMC: 4708194. DOI: 10.2147/DDDT.S97221.